Eris Lifesciences Limited
Eris Lifesciences Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹873 cr of revenue in its latest quarter (Q1 FY27) and kept 16.3% of sales as profit.
“Eris derives 95% of its revenues from the domestic branded The evolution in therapeutic mix resulting from acquisitions formulations market. Chronic and sub-chronic therapies undertaken during the last two fiscal years has been account for 82% of our business (vs 53% for IPM). instrumental in shaping our business profile and growth prospects.”
Healthier than 54% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 33–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 40
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in ERIS?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 9%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹873 cr |
| Other Income | ₹2 cr |
| Total Income | ₹876 cr |
| Cost of Materials | ₹94 cr |
| Purchases of Stock-in-Trade | ₹131 cr |
| Inventory Change (±) | ₹14 cr |
| Employee Benefit Expense | ₹153 cr |
| Finance Costs | ₹47 cr |
| Depreciation & Amortisation | ₹72 cr |
| Other Expenses | ₹184 cr |
| Total Expenses | ₹696 cr |
| Profit before Tax | ₹180 cr |
| Tax Expense | ₹36 cr |
| Share of JV / Associates | ₹-40 L |
| Net Profit | ₹143 cr |
| Net margin on total income | 16.4% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 807 cr | 757 cr | 873 cr |
| Total income | 807 cr | 759 cr | 876 cr |
| Expenses | 645 cr | 598 cr | 696 cr |
| Profit before tax | 145 cr | 161 cr | 180 cr |
| Tax | 37 cr | -120 cr | 36 cr |
| Net profit (owners' share) | 100 cr | 282 cr | 142 cr |
| Net margin (owners' share, on revenue) | 12.3% | 37.2% | 16.3% |
| EPS (₹) | 7.32 | 20.60 | 10.28 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹7.21 / share | 29 May 2026 |
| Dividend | ₹7.35 / share | 13 Feb 2025 |
| Dividend | ₹7.35 / share | 11 Aug 2022 |
| Dividend | ₹6.01 / share | 5 Aug 2021 |
| Dividend | ₹5.5 / share | 13 Aug 2020 |
| Dividend | ₹2.87 / share | 19 Mar 2020 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 9 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.